Medicure Sales And Marketing Effort Underway Following Aggrastat Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck separately acquires the right of first refusal for a combination of Aggrastat and Medicure’s investigational cardio-protective compound, the firm says.